Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada warns against sex enhancement drug

This article was originally published in The Tan Sheet

Executive Summary

Canadian consumers are warned against using Adam, an unauthorized product for erectile dysfunction, as it may pose serious health risks, especially for patients with pre-existing medical conditions, Health Canada says in a statement March 10. The product contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil, which is used under the supervision of a physician, the agency says. Heart disease patients who use sildenafil can experience cardiovascular side effects including heart attack and stroke, Health Canada notes. Distributor Natural Health Solutions conducted a voluntary recall of Adam, which was sold in retail outlets throughout Canada and on the Internet. Due to the proliferation of erectile dysfunction supplements containing prescription ingredients in the U.S., the United Natural Products Alliance is urging the supplement industry to take steps to keep these products off the market (1"The Tan Sheet" Jan. 28, 2008, p. 11)...

You may also be interested in...



FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel